VIBLIOME

Vibliome has discovered a new systematic approach that enables the development of small molecule kinase inhibitors with unique selectivity profiles and, in some cases, extraordinary selectivity. There are over 500 kinases in the human genome which control nearly all cellular functions by transferring a polar phosphate group from ATP to regulatory serine, threonine, or tyrosine residues on proteins. The versatility of our chemistry platform offers many opportunities for variation while maintaining a common general architecture.